Search research articles
Contact Us
Filters
Showing results (71-80 of 87) with videos related to
Page
of 9
Sort By:
Haematologica
|
March 13, 2025
Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow up
Andrew J Portuguese, Jennifer J Huang, Yein Jeon, et al.
Transplantation and Cellular Therapy
|
August 2, 2025
Opportunities to Improve Antibiotic Stewardship, and Identification of Blood Biomarkers Associated with Bacteremia Following CAR-T Cell Therapy
Sai Kit Ng, Patrick W Flaherty, Melissa Ancheta, et al.
Immunity
|
October 3, 2025
Eomesodermin<sup>+</sup> CD4<sup>+</sup> T cells are critical for curative immunotherapy outcomes
Ping Zhang, Françoise Haeseleer, Olivia G Waltner, et al.
Blood Advances
|
October 30, 2023
Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma
Alexandre V Hirayama, Erik L Kimble, Jocelyn H Wright, et al.
Blood
|
February 8, 2019
Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy
Kevin A Hay, Jordan Gauthier, Alexandre V Hirayama, et al.
Transplantation and Cellular Therapy
|
April 9, 2023
Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy
Nicolas Gazeau, Emily C Liang, Qian Vicky Wu, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
October 16, 2024
Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Bijal Shah, Ryan J Mattison, Ramzi Abboud, et al.
Blood
|
September 23, 2020
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies
Jordan Gauthier, Evandro D Bezerra, Alexandre V Hirayama, et al.
Blood
|
February 21, 2019
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells
Alexandre V Hirayama, Jordan Gauthier, Kevin A Hay, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 22, 2021
Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Patrick A Brown, Bijal Shah, Anjali Advani, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 87) with videos related to
Sort By:
Page
of 9
Haematologica
|
March 13, 2025
Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow up
Andrew J Portuguese, Jennifer J Huang, Yein Jeon, et al.
Transplantation and Cellular Therapy
|
August 2, 2025
Opportunities to Improve Antibiotic Stewardship, and Identification of Blood Biomarkers Associated with Bacteremia Following CAR-T Cell Therapy
Sai Kit Ng, Patrick W Flaherty, Melissa Ancheta, et al.
Immunity
|
October 3, 2025
Eomesodermin<sup>+</sup> CD4<sup>+</sup> T cells are critical for curative immunotherapy outcomes
Ping Zhang, Françoise Haeseleer, Olivia G Waltner, et al.
Blood Advances
|
October 30, 2023
Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma
Alexandre V Hirayama, Erik L Kimble, Jocelyn H Wright, et al.
Blood
|
February 8, 2019
Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy
Kevin A Hay, Jordan Gauthier, Alexandre V Hirayama, et al.
Transplantation and Cellular Therapy
|
April 9, 2023
Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy
Nicolas Gazeau, Emily C Liang, Qian Vicky Wu, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
October 16, 2024
Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Bijal Shah, Ryan J Mattison, Ramzi Abboud, et al.
Blood
|
September 23, 2020
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies
Jordan Gauthier, Evandro D Bezerra, Alexandre V Hirayama, et al.
Blood
|
February 21, 2019
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells
Alexandre V Hirayama, Jordan Gauthier, Kevin A Hay, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 22, 2021
Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Patrick A Brown, Bijal Shah, Anjali Advani, et al.
Page
of 9